Перименопауза: от контрацепции к заместительной гормональной терапии. Преимущества дроспиренона (В помощь практикующему врачу)

1. Hannaford PC, Selvaraj S, Elliott AM et al. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner’s oral contraception study. BMJ 2007; 335: 651.
2. Vessey M, Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968–2004. Br J Cancer 2006; 95: 385–9.
3. Beral V, Doll R, Hermon C et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23, 257 women with ovarian cancer and 87,303 controls. Lancet 2008; 371: 303–14.
4. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998; 179: 577–82.
5. Scouby SO. Contraceptive use and behavior in the 21st century: a comprehensive study across five European countries. Eur J Contracept Reprod Health Care 2004; 9: 57–68.
6. Oelkers WK. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids 1996; 61: 166–71.
7. Rosano GM, Vitale C, Tulli A. Managing cardiovascular risk in menopausal women. Climacteric 2006; 9 (Suppl. 1): 19–27.
8. Perchere-Betschi A, Bunier M. Female sex hormones, salt and blood pressure regulation. Am J Hypertens 2004; 17: 994–1001.
9. Hernandez Schulman I, Aranda P, Raij L. Surgical menopause increases salt sensitivity of blood pressure. Hypertension 2006; 47: 1168–74.
10. Vasan RS, Larson MG, Leip EP et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345 (18): 1291–7.
11. Oelkers W, Foidart JM, Dombrovicz N et al. Effects of a new oral contraceptive containing an antimineralocorticoid proges-togen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995; 80: 1816–21.
12. Прилепская В.Н. Руководство по контрацепции. М., 2006.
13. Halbreich U, Backstrom T, Eriksson E et al. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies Gynecological Endocrinology 2007; 23 (3): 123–30.
14. Angst J, Sellaro R, Stolar M et al. The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr Scand 2001; 104: 110–6.
15. Borenstein JE, Dean BB, Endicott J et al. Health and economic impact of the premenstrual syndrome. J Reprod Med 2003; 48: 515–24.
16. Chawla A, Swindle R, Long S et al. Premenstrual dysphoric disorder: is there an economic burden of illness? Med Care 2002; 40: 1101–12.
17. Halbreich U. The diagnosis of premenstrual syndromes and premenstrual dysphoric disorder – clinical procedures and research perspectives. Gyn Endocrinol 2004; 19: 320–34.
18. Wittchen HU, Becker E, Lieb R, Krause P. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 2002; 32: 119–32.
19. Endicott J, Nee J, Harrison W. Daily Record of Severity of Problems (DRSP): reliability and validity. Arch Women Ment Health 2006; 9: 41–9.
20. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005; 72: 414–21.
21. Maloney JM, Kunz M, Lee-Rugh S et al. Drospirenone 3 mg/ethinylestradiol 20 mcg combined oral contraceptive in the treatment of acne vulgaris: lesion count, ISGA. Obstet Gynecol 2007; 109: 11S.
22. Koltun W, Lucky AW, Thiboutot D et al. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: A randomized, double-blind, placebo-controlled trial. Contraception 2008; 77: 249–56.
23. Gray RH. Biological and social interactions in determination of late fertility. J Biosoc Sci 1979; Suppl. 6: 97–115.
24. Archer DF, Thorneycroft IH, Foegh M et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005; 12: 716–27.
25. White WB, Pitt B, Preston RA, Hanes V. Effect of a New Hormone therapy, DRSP and 17 b-E2 in Postmenopausal Women with Hypertension. Hypertension 2006; 48: 1–8.
26. Прилепская В.Н. Новые возможности и перспективы современной контрацепции. Пробл. репродукции. 2009; 5: 59–61.
27. Knuuiti J, Kallokoski R, Janatuinen T et al. Effect of estradiol-drospirenone hormone treatment on myocardial perfusion reserve in postmenopausal women with angina pectoris. Am J Cardiol 2007; 99: 1648–52.
28. Carpio M, Zennaro M-C, Feve B et al. Potential role of progestogens in the control of adipose tissue and salt sensitivity via interaction with mineralocorticoid receptor. Climacteric 2008; 11: 258–64.
29. Tanko LB, Christiansen C. Effects of 17 b-oestradiol plus different doses of drospirenone on adipose tissue, adiponectin and atherogenic metabolites in postmenopausal women. J Internal Med 2005; 258: 544–53.
30. Порывкина О.Н., Адашева Т.В., Задионченко В.С. и др. Эффективность и безопасность применения препарата Анжелик у пациенток с метаболическим синдромом в постменопаузе. 2008.

________________________________________________

1. Hannaford PC, Selvaraj S, Elliott AM et al. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner’s oral contraception study. BMJ 2007; 335: 651.
2. Vessey M, Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968–2004. Br J Cancer 2006; 95: 385–9.
3. Beral V, Doll R, Hermon C et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23, 257 women with ovarian cancer and 87,303 controls. Lancet 2008; 371: 303–14.
4. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998; 179: 577–82.
5. Scouby SO. Contraceptive use and behavior in the 21st century: a comprehensive study across five European countries. Eur J Contracept Reprod Health Care 2004; 9: 57–68.
6. Oelkers WK. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids 1996; 61: 166–71.
7. Rosano GM, Vitale C, Tulli A. Managing cardiovascular risk in menopausal women. Climacteric 2006; 9 (Suppl. 1): 19–27.
8. Perchere-Betschi A, Bunier M. Female sex hormones, salt and blood pressure regulation. Am J Hypertens 2004; 17: 994–1001.
9. Hernandez Schulman I, Aranda P, Raij L. Surgical menopause increases salt sensitivity of blood pressure. Hypertension 2006; 47: 1168–74.
10. Vasan RS, Larson MG, Leip EP et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345 (18): 1291–7.
11. Oelkers W, Foidart JM, Dombrovicz N et al. Effects of a new oral contraceptive containing an antimineralocorticoid proges-togen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995; 80: 1816–21.
12. Прилепская В.Н. Руководство по контрацепции. М., 2006.
13. Halbreich U, Backstrom T, Eriksson E et al. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies Gynecological Endocrinology 2007; 23 (3): 123–30.
14. Angst J, Sellaro R, Stolar M et al. The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr Scand 2001; 104: 110–6.
15. Borenstein JE, Dean BB, Endicott J et al. Health and economic impact of the premenstrual syndrome. J Reprod Med 2003; 48: 515–24.
16. Chawla A, Swindle R, Long S et al. Premenstrual dysphoric disorder: is there an economic burden of illness? Med Care 2002; 40: 1101–12.
17. Halbreich U. The diagnosis of premenstrual syndromes and premenstrual dysphoric disorder – clinical procedures and research perspectives. Gyn Endocrinol 2004; 19: 320–34.
18. Wittchen HU, Becker E, Lieb R, Krause P. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 2002; 32: 119–32.
19. Endicott J, Nee J, Harrison W. Daily Record of Severity of Problems (DRSP): reliability and validity. Arch Women Ment Health 2006; 9: 41–9.
20. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005; 72: 414–21.
21. Maloney JM, Kunz M, Lee-Rugh S et al. Drospirenone 3 mg/ethinylestradiol 20 mcg combined oral contraceptive in the treatment of acne vulgaris: lesion count, ISGA. Obstet Gynecol 2007; 109: 11S.
22. Koltun W, Lucky AW, Thiboutot D et al. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: A randomized, double-blind, placebo-controlled trial. Contraception 2008; 77: 249–56.
23. Gray RH. Biological and social interactions in determination of late fertility. J Biosoc Sci 1979; Suppl. 6: 97–115.
24. Archer DF, Thorneycroft IH, Foegh M et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005; 12: 716–27.
25. White WB, Pitt B, Preston RA, Hanes V. Effect of a New Hormone therapy, DRSP and 17 b-E2 in Postmenopausal Women with Hypertension. Hypertension 2006; 48: 1–8.
26. Прилепская В.Н. Новые возможности и перспективы современной контрацепции. Пробл. репродукции. 2009; 5: 59–61.
27. Knuuiti J, Kallokoski R, Janatuinen T et al. Effect of estradiol-drospirenone hormone treatment on myocardial perfusion reserve in postmenopausal women with angina pectoris. Am J Cardiol 2007; 99: 1648–52.
28. Carpio M, Zennaro M-C, Feve B et al. Potential role of progestogens in the control of adipose tissue and salt sensitivity via interaction with mineralocorticoid receptor. Climacteric 2008; 11: 258–64.
29. Tanko LB, Christiansen C. Effects of 17 b-oestradiol plus different doses of drospirenone on adipose tissue, adiponectin and atherogenic metabolites in postmenopausal women. J Internal Med 2005; 258: 544–53.
30. Порывкина О.Н., Адашева Т.В., Задионченко В.С. и др. Эффективность и безопасность применения препарата Анжелик у пациенток с метаболическим синдромом в постменопаузе. 2008.

В.Н.Прилепская, В.П.Сметник

ФГУ Научноый центр акушерства, гинекологии и перинатологии Росмедтехнологий им. В.И. Кулакова
(дир. – Акад. РАМН, д.м.н., проф. Г.Т. Сухих), Москва